The Stucky group began work on controlling bleeding by focusing on materials for external hemorrhage, mainly layered clays. This research resulted in the development of QuikClot Combat Gauze, which is still currently used today. The searches for non-toxic alternatives lead to research on silica mesocelllular foam (MCF). This research was done in collaboration with Daniele Zink at the Institute of Bioengineering and Nanotechnology, Singapore. Cytotoxicity studies were done on six cell lines with various layered clays, and MCF, which were also tested for their clotting abilities. The next challenge was to develop a method specifically targeting internal hemorrhage. While there are multiple products available to treat external hemorrhage there is no product on the market that can target and control internal hemorrhage. It remains the foremost cause of preventable death on the battlefield and the second leading cause of preventable death in civilian trauma. There is a driving force to develop a product that can halt internal bleeding until surgical attention can be provided. Research began with the development of a biocompatible nanoparticle carrier that can deliver a coagulation amplifier to the site of internal injury. Polymer nanoparticles were created to deliver thrombin, a coagulation protein, and polyphosphate, a known coagulation accelerator. The synthesis and development of a biocompatible nanoparticle carrier lead to the development of a strong anticoagulant nanoparticle. The nanoparticle was also successfully functionalized with polyphosphate and tested for coagulation abilities. Significant progress was made on the development of a delivery vehicle for a coagulation accelerator. This functionalized nanoparticle was non-toxic to both HUVEC and HPTC cell lines.